Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

October 07, 2024

Isabel Preeshagul, DO, MBS, and colleagues share updates from across the lung cancer space as discussed in a recent State of the Science Summit.

October 04, 2024

Isabel Preeshagul, DO, MBS, discusses considerations for treatment selection in the first and second line for patients with EGFR-mutated NSCLC.

October 03, 2024

Mark Awad, MD, PhD, discusses the significance of the FDA approval of perioperative nivolumab for patients with resectable NSCLC.

October 03, 2024

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses challenges of integrating bispecific antibodies and CAR T-cell therapies into the community for myeloma.

October 02, 2024

MRD negativity was sustained at 1 year following the cessation of maintenance lenalidomide in multiple myeloma.

October 01, 2024

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the efficacy of daratumumab plus VRd in patients with transplant-ineligible or -deferred multiple myeloma.

September 27, 2024

Daratumumab plus VRd improved MRD-negativity rates in transplant-ineligible or -deferred, newly diagnosed multiple myeloma.

September 14, 2024

The novel ALK inhibitor NVL-655 demonstrated encouraging activity in heavily pretreated patients with advanced ALK-positive NSCLC.

September 07, 2024

A 12-mg/kg dose of ifinatamab deruxtecan improved efficacy compared with an 8-mg/kg dose in heavily pretreated patients with extensive-stage small cell lung cancer.

September 04, 2024

Sergio A. Giralt, MD, discusses how to determine transplant eligibility and the evolving role of transplant for patients with myelodysplastic syndromes.

August 26, 2024

Ciara Kelly, MBBCh, BAO, discusses ongoing trials to further enhance the treatment of patients with gastrointestinal stromal tumor.

August 23, 2024

Ciara Kelly, MBBCh, BAO, discusses the evaluation of DCC-3116 in combination with ripretinib in advanced gastrointestinal stromal tumor.

August 22, 2024

Dr Jhaveri discusses the INAVO120 trial of inavolisib plus palbociclib and fulvestrant in PIK3CA-mutant, HR-positive metastatic breast cancer.

August 21, 2024

Ciara Kelly, MBBCh, BAO, discusses the importance of genetic abnormality testing for patients with gastrointestinal stromal tumors.

August 19, 2024

Neil J. Shah, MBBS, discusses real-world outcomes of patients with metastatic RCC receiving treatment in the post-IO/TKI setting following progression.

August 19, 2024

Rona Yaeger, MD, details the FDA approval of adagrasib plus cetuximab in KRAS G12C-mutated colorectal cancer and how the approval will advance the field.

August 16, 2024

Investigators are developing preventive interventions to identify patients most at risk for financial toxicity and offer them assistance.

August 13, 2024

Samuel Cytryn, MD, and David B. Zhen, MD, discuss how immunotherapy plus chemotherapy has improved the durability of outcomes in advanced GI cancers.

August 13, 2024

Samuel Cytryn, MD, and David B. Zhen, MD, on factors for selecting nivolumab plus chemotherapy or ipilimumab in esophageal squamous cell carcinoma.

August 13, 2024

Samuel Cytryn, MD, and David B. Zhen, MD, on long-term data for nivolumab plus chemotherapy or ipilimumab in advanced esophageal squamous cell carcinoma.